Compare MYE & IVA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | MYE | IVA |
|---|---|---|
| Founded | 1933 | 2011 |
| Country | United States | France |
| Employees | N/A | 77 |
| Industry | Auto Parts:O.E.M. | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.3B | 1.1B |
| IPO Year | 1995 | 2020 |
| Metric | MYE | IVA |
|---|---|---|
| Price | $32.80 | $4.71 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 1 | 10 |
| Target Price | ★ $26.00 | $16.20 |
| AVG Volume (30 Days) | 351.6K | ★ 641.2K |
| Earning Date | 05-07-2026 | 03-30-2026 |
| Dividend Yield | ★ 2.71% | N/A |
| EPS Growth | ★ 389.47 | N/A |
| EPS | ★ 0.48 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $0.87 | N/A |
| Revenue Next Year | $1.83 | $751.20 |
| P/E Ratio | $69.35 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $15.54 | $3.35 |
| 52 Week High | $37.45 | $7.98 |
| Indicator | MYE | IVA |
|---|---|---|
| Relative Strength Index (RSI) | 51.52 | 52.02 |
| Support Level | $32.08 | $4.46 |
| Resistance Level | $35.75 | $4.70 |
| Average True Range (ATR) | 0.95 | 0.16 |
| MACD | -0.18 | -0.00 |
| Stochastic Oscillator | 42.24 | 43.40 |
Myers Industries Inc designs, manufactures, and markets a variety of plastic, metal, and rubber products, including a broad selection of plastic reusable containers, pallets, small parts bins, bulk shipping containers, storage and organization products, OEM parts, custom plastic products, consumer fuel containers and tanks for water, fuel and waste handling. It operates through the following segments: The Material Handling segment manufactures a selection of durable plastic reusable products that are used repeatedly during the course of their service life. The Distribution segment is engaged in the distribution of equipment, tools, and supplies used for tire servicing and automotive under-vehicle repair, etc. It generates the majority of its revenue from the Material Handling segment.
Inventiva SA is a France-based clinical-stage biopharmaceutical company focused on the development of oral small-molecule therapies for the treatment of MASH. The wholly-owned research and development facility and a team with expertise and experience in the development of compounds that target nuclear receptors, transcription factors and epigenetic modulation. Leveraging the expertise, the company is also advancing lanifibranor for the treatment of MASH and has a pipeline of earlier-stage therapeutic programs in oncology. It operates in the segment of Service delivery and clinical stage research, notably into therapies in the areas of oncology, fibrosis, and rare diseases. All the company's operations are in France.